NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

RenovoRx, Inc. (RNXT) Stock Analysis

RenovoRx, Inc. (RNXT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RNXT

$2.39

+$0.02 (+0.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNXT with… →

RNXT Key Statistics

As of Sep 4, 2026
Trading
Open
$2.35
Previous Close
$2.37
Day's Range
2.28–2.54
52-Week Range
0.70–2.59
Volume
2.09M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.12
Valuation
Market Cap
$107.86M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
54.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.31
Financials (FY)
Revenue (FY)
$1.12M+2511.63%
Net Income (FY)
−$11.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.13M
1-Year Return
+100.84%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
563.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RNXT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+184.52%
2025−34.88%
2024−43.67%
2023−2.55%
2022−51.45%
2021 (partial year)−33.33%

As of September 4, 2026.

RNXT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.12M−$11.17M−994.5%
2024$43.00K−$8.81M−20497.7%
2023$0.00−$10.23M—
2022$0.00−$9.89M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.12M$796.00K−$12.51M−$11.17M−994.5%
2024$43.00K$43.00K−$10.97M−$8.81M−20497.7%
2023$0.00$0.00−$11.40M−$10.23M—
2022$0.00—−$9.95M−$9.89M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RNXT Valuation vs Biotechnology Median

Median of 656 stocks
MetricRNXTBiotechnology medianvs median
P/S ratio54.5815.263.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values RenovoRx, Inc. (RNXT) at $107.86M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 17.

The 52-week range on file runs from $0.70 to $2.59. RNXT last closed at $2.39 on September 4, 2026. That is +$0.02 (+0.84%) against the previous close. The latest close sits 240.94% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.12M. That is +2,511.63% against the prior fiscal year, when revenue was $43.00K. The same year closed with a net loss of $11.17M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.31.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 54.58 times revenue. On price-to-sales that is 3.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +100.84%. Measured over 5 years, that is −21.25% a year compounded. Beta against the wider market is reported at 1.12. Annualized volatility over the trailing 5 years is 100.93%.

Growth & Income

The record shows no dividend for RNXT.

So far in 2026 the price is +184.52%. The strongest complete calendar year on file is 2023 at −2.55%; the weakest is 2022 at −51.45%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

RenovoRx, Inc. (RNXT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
RenovoRx, Inc. RNXT $107.86M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. RenovoRx, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.

Visit website →